Friday, March 15, 2019 11:09:16 AM
FDA @ work!
Ketamine works great for depression and other conditions, and costs $10/dose; the new FDA-approved "ketamine" performs badly in trials and costs a fortune
FROM THE BOING BOING SHOP
Ketamine is a sedative first synthesized in 1962; its patents have long elapsed and it costs pennies; it has many uses and is also sold illegally for use as a recreational drug, but in recent years it has been used with remarkable efficacy as a treatment for a variety of disorders, including depression, anxiety, and chronic pain (I have lifelong chronic pain and my specialist has prescribed very low doses of it for me at bedtime).
Recently, the FDA approved Esketamine, a ketamine-like drug in a nasal spray for use as fast-acting relief, but Johnson & Johnson, the company that developed Esketamine, has only done four efficacy studies of mixed results. Esketamine isn't ketamine: it's a mirror-image of the ketamine molecule ("left-handed ketamine," or "S-for-sinister-ketamine"). This mirroring is what let Johnson & Johnson get a patent on a drug that's been around since 1962.
So why is Esketamine -- new, largely unstudied and unpromising -- approved for use, while ketamine -- old, well-studied, and widely used -- still off-label for treating depression and pain?
Scott Alexander (previously) has a theory: "I suspect this was a political move based on how embarrassing it was to have everyone know ketamine was a good antidepressant, but not have it officially FDA-approved."
Alexander goes into some detail on Estketamine's background, which is bound up in the (pretty terrible) history of antidepressants, as well as the limitations on administering ketamine infusions (which require patients to be sedated and hallucinating, while under medical supervision, for hours at a stretch, or even many consecutive days).
The FDA, in its approval for esketamine, specified that it could only be delivered at specialty clinics by doctors who are specially trained in ketamine administration, that patients will have to sit at the clinic for at least two hours, and realistically there will have to be a bunch of nurses on site. My boss has already said our (nice, well-funded) clinic isn’t going to be able to jump through the necessary hoops; most other outpatient psychiatric clinics will probably say the same.
This removes most of the advantages of having it be intranasal, so why are they doing this? They give two reasons. First, they want to make sure no patient can ever bring ketamine home, because they might get addicted to it. Okay, I agree addiction is bad. But patients bring prescriptions of OxyContin and Xanax home every day. Come on, FDA. We already have a system for drugs you’re worried someone will get addicted to, it’s called the Controlled Substances Act. Ketamine is less addictive than lots of chemicals that are less stringently regulated than it is. This just seems stupid and mean-spirited.
The other reason the drugs have to be given in a specially monitored clinic is because ketamine can have side effects, including hallucinations and dissociative sensations. I agree these are bad, and I urge patients only to take hallucinogens/dissociatives in an appropriate setting, such as a rave. Like, yeah, ketamine can be seriously creepy, but now patients are going to have to drive to some overpriced ketamine clinic a couple of times a week and sit there for two hours per dose just because you think they’re too frail to handle a dissociative drug at home?
Ketamine: Now By Prescription [Scott Alexander/Slate Star Codex]
SHARE / TWEET / 31 COMMENTS
CHRONIC PAIN / CORRUPTION / DEPRESSION / ESKETAMINE / HEALTH / KETAMINE / PHARMA
Recent XXII News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 09:30:52 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 02/14/2024 09:10:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 01:30:13 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 01/24/2024 09:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2024 01:04:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/28/2023 09:30:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/21/2023 10:02:41 PM
- 22nd Century Secures $3.2 Million to Date in Warrant Exchange Transaction • GlobeNewswire Inc. • 12/04/2023 12:07:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 12/01/2023 10:18:00 PM
- Pharma Stock Up Big After Second Major Announcement This Week • AllPennyStocks.com • 11/29/2023 03:55:00 PM
- Pharma Stock Up Big After Second Major Announcement This Week • AllPennyStocks.com • 11/29/2023 03:55:00 PM
- 22nd Century Appoints Larry Firestone as Chairman and CEO • GlobeNewswire Inc. • 11/29/2023 12:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/27/2023 09:56:49 PM
- 22nd Century Group Enters into Agreement to Sell Hemp/Cannabis Franchise • GlobeNewswire Inc. • 11/27/2023 09:44:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/13/2023 11:01:36 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/08/2023 10:19:32 PM
- 22nd Century Group Continues VLN® Expansion, Now Retailing in More Than 5,100 Stores • GlobeNewswire Inc. • 11/08/2023 06:15:00 PM
- 22nd Century Group (XXII) Expands Reduced Nicotine Content Tobacco IP with Latest Technology License • GlobeNewswire Inc. • 11/07/2023 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/06/2023 12:30:19 PM
- 22nd Century Group (XXII) Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/06/2023 12:30:00 PM
- 22nd Century Group (XXII) Supports FDA Policy Advancements, Proposed Menthol Ban Now at OMB • GlobeNewswire Inc. • 10/26/2023 12:30:00 PM
- 22nd Century Group (XXII) Reduces Debt by $8.1 Million • GlobeNewswire Inc. • 10/25/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/18/2023 08:34:05 PM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM
Kona Gold Beverages, Inc. Prepares for First Production Run Set to Launch May 17, 2024 • KGKG • Apr 22, 2024 8:30 AM